Forty-Four (44) Bioactive Compounds for the MIPE 6. 0 Expansion at NCATS (Brand-Name or Equal)
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is 75N95022Q00481 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures and FAR Part 12—Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition teshold. The Government anticipates award of a firm fixed-price purchase order for this acquisition, and the anticipated award date is on or around August 31, 2022. (iii) The solicitation document and incorporated provisions and clauses are those in effect tough Federal Acquisition Circular (FAC) Number 2022-07 dated August 10, 2022. (iv) This acquisition is full and open with no set-aside restrictions. The associated NAICS code is 325414 and the small business size standard is 1,250 employees. DESCRIPTION (v) This brand-name or equal acquisition is for forty-four (44) bioactive compounds for replenishment and expansion of the Mechanism Interrogation Plate (MIPE) screening library for the NCATS. The purchase description with the salient characteristics the brand-name or equal items must meet is included as Attachment 1 to this Solicitation. (vi) The place of delivery and acceptance shall be: The National Center for Advancing Translational Sciences (NCATS) 9800 Medical Center Drive Rockville, MD 20850 Delivery shall be within fifty (50) days after receipt of order (ARO). Delivery will be f.o.b. destination, and the quotation’s total price must include all shipping and handling costs. PROVISIONS, CLAUSES, AND OTHER TERMS AND CONDITIONS (vii) The provision at FAR clause 52.212-1, Instructions to Offerors – Commercial Products and Commercial Services applies to this acquisition. (viii) The Government will perform a comparative evaluation of responses in accordance with FAR 13.106-2(b)(3) and award a purchase order from this solicitation to the responsible offeror whose response meets the solicitation’s requirements and, as a whole, will be most advantageous to the Government, price and other factors considered. The evaluation will compare: Technical Capability of the service to meet the Government requirement, Price, and Past Performance as defined under FAR 13.106-2(b)(3). If only one quotation is received it will be evaluated on the preceding. (ix) Offerors are to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Products and Commercial Services, with offers. Offerors are also to complete the attached provisions at FAR FAR 52.204-26, FAR 52.204-24 if applicable, and FAR 52.225-4 with their offers. Alternatively, these representations and certifications must be completed within Offerors’ active SAM.gov registrations at the time of the Government’s receipt of a response to this Solicitation, and they shall apply to their response and be relied upon by the Government. (x) The provision at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html (End of provision) The following provisions apply to this acquisition and are incorporated by reference: FAR 52.204-7, System for Award Management (Oct 2018) FAR 52.204-16, Commercial and Government Entity Code Reporting (Aug 2020) FAR 52.211-6, Brand Name or Equal (Aug 1999) FAR 52.214-34, Submission of Offers in the English Language (Apr 1991) FAR 52.214-35, Submission of Offers in U.S. Currency (Apr 1991) FAR 52.225-4, Buy American-Free Trade Agreements-Israel Trade Act Certificate (Feb 2021) Alternate I (Jan 2021) The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html (End of clause) The following clauses apply to this acquisition and are incorporated by reference: FAR 52.204-13, System for Award Management Maintenance (Oct 2018) FAR 52.204-18, Commercial and Government Entity Code Maintenance (Aug 2020) FAR 52.204-21, Basic Safeguarding of Covered Contractor Information Systems (Nov 2021) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015) HHSAR 352.223-70, Safety and Health (December 18, 2015) The following provisions and clauses apply to this acquisition and are attached in full text: FAR 52.204-24, Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Nov 2021) FAR 52.204-26, Covered Telecommunications Equipment or Services-Representation (Oct 2020) FAR 52.225-4, Buy American-Free Trade Agreements-Israel Trade Act Certificate (Feb 2021) Alternate I (Jan 2021) Invoice and Payment Provisions (Vendor Has Transitioned to IPP). Addendum to these invoicing instructions applies to this acquisition as follows: the Contractor will invoice for payment upon completed deliveries. (xi) The clause at FAR 52.212-4, Contract Terms and Conditions-Commercial Products and Commercial Services, applies to this acquisition and an addendum is attached in full text. (xii) The clause at FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Products and Commercial Services, applies to this acquisition and is attached in full text. (xiii) This is a brand-name or equal acquisition. The items under this acquisition are subject to Free Trade Agreements. SUBMISSION INSTRUCTIONS (xiv) Responses to this solicitation must include sufficient information to establish the interested parties’ bona-fide capabilities of providing the product or service. The response shall contain a quotation that includes the total price, as well as: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s), product description, and any other information or factors that may be considered in the award decision. Such factors may include: past performance, special features required for effective program performance, trade-in considerations, probable life of the item selected as compared with that of a comparable item, warranty considerations, maintenance availability, and environmental and energy efficiency considerations. Respondents proposing on an equal product of the brand-name product specified in this announcement must provide, as part of their response: (a) product, catalog, model, and/or part number(s); (b) product description; (c) all relevant information and documentation that the item(s) offered meets the salient physical, functional, or performance characteristics as specified in the purchase description; quantity; estimated price or cost; shipping, handling, and/or installation charges; and delivery date after receipt of order. The Unique Entity Identifier (UEI), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All responses must be received by 05:00 PM, EDT on August 25, 2022, and reference Solicitation Number 75N95022Q00481 Responses must be submitted by email to the Contracting Officer at mark.mcnally@nih.gov. (xv) The name and telephone number of the individual to contact for information regarding the solicitation: Mark McNally, Contracting Officer, 301-827-5869, mark.mcnally@nih.gov. 75N95022Q00481 Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse
8/18/22, 4:18 PM Forty-Four (44) Bioactive Compounds for the MIPE 6. 0 Expansion at NCATS
This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition; and (4) availability of domestic sources manufactured in the United States in sufficient and reasonably available commercial quantities and of a satisfactory quality. Responses must include the place of manufacturing (i.e. address if supply/equipment is a domestic end product and include country of manufacture). Small businesses must also address the size status of the manufacturer under the applicable NAICS code (i.e. address Non-Manufacturer Rule). Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Background: The Division of Preclinical Innovation (DPI) within the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), has a multidisciplinary team that developed a high-capacity robotic platform to screen drug combinations. In just a couple of days, the robots can perform a drug screen that would take human researchers months to complete. DPI develops and oversees the tests (called "assays") that run on the platform. The system performs the automated assays using diseased cells that are placed on plates in tiny indentations called wells. Cells are treated in each well with a unique combination of drugs, and the assays reveal the effects of the drugs on each group of cells. One feature that makes the platform stand out from previous combination drug screening efforts is the drug library it uses, called the Mechanism Interrogation PlatE (MIPE). All the drugs in the MIPE collection are relevant for clinical use in cancer and have mechanisms of action that scientists already understand. The observations of each drug pair’s effects on the target cells, coupled with the detailed knowledge about the compounds in the MIPE library, provide the researchers with insights into the interactions between various cellular processes. This library not only enables DPI to find compound combinations that can go rapidly into clinical trials, but also explore the biological processes that create the enhanced effect of a drug combination in a cell, leading to new drug targets. The evolution of the MIPE library requires regular updating with new agents. The MIPE 6.0 expansion will incorporate a number of new agents and further the potential of chemogenomic screening at NCATS. Purpose and Objectives: To acquire forty-four (44) specified agents for replenishment and expansion of the MIPE screening library. Project requirements: The contractor shall deliver the following compounds. The compounds shall be packaged and shipped in accordance with industry practices to avoid damage and ensure safe delivery and receipt: Name CAS Unit Size Quantity Derenofylline 251945-92-3 5mg 1 SR-3306 1128096-91-2 5mg 1 Gefitinib-based PROTAC 3 2230821-27-7 10mg 1 Anisina 1861449-70-8 10mg 1 ALW-II-41-27 1186206-79-0 5mg 1 BMS-1166 1818314-88-3 5mg 1 LY-2857785 1619903-54-6 5mg 1 OSU-T315 1333146-24-9 5mg 1 MD-224 2136247-12-4 10mg 1 Supinoxin 888478-45-3 5mg 1 HG-6-64-1 1315329-43-1 5mg 1 PTC-691 420126-30-3 5mg 1 GMB-475 None assigned 10mg 1 S-64315 1799631-75-6 10mg 1 ACBI-1 2375564-55-7 10mg 1 BETd-260 2093388-62-4 10mg 1 MZP-55 2010159-48-3 10mg 1 MZP-54 2010159-47-2 10mg 1 Motixafortide 664334-36-5 25mg 1 Voclosporin 515814-01-4 10mg 1 BETd-246 2140289-17-2 10mg 1 ADU-S100 1638750-95-4 10mg 1 Dolastatin 10 110417-88-4 5mg 2 GNE-987 None assigned 10mg 1 JH-XI-10-02 2209085-22-1 10mg 1 BI-3663 2341740-84-7 10mg 1 Eribulin 441045-17-6 10mg 1 Lurbinectedin 497871-47-3 2mg 3 BI605906 960293-88-3 10mg 1 BAI1 335165-68-9 10mg 1 Pelcitoclax None assigned 10mg 1 HA14-1 65673-63-4 50mg 1 Maritoclax 1227962-62-0 10mg 1 S65487 1644600-79-2 10mg 1 Necrosulfonamide 1360614-48-7 25mg 1 GSK2983559 1423186-80-4 10mg 1 JNJ-67856633 2230273-76-2 10mg 1 Phorbol 12-myristate 13-acetate (PMA) 16561-29-8 25mg 1 MLT-943 1832576-04-1 10mg 1 T6167923 2437475-16-4 10mg 1 MLT-748 1832578-30-9 10mg 1 TC13172 2093393-05-4 10mg 1 Alflutinib 2130958-55-1 10mg 1 ALDH1A1-IN-2 2231081-18-6 10mg 1 The salient characteristics for all of the compounds shall include: The quantity and weight as listed above. Confirmed purity greater than 98% (>98). Meet the chemical description under the Chemical Abstract Service (CAS). The CAS Registry Numbers are unique numerical identifiers assigned by the CAS to every chemical described in the open scientific literature and including elements, isotopes, organic and inorganic compounds, ions, organometallics, metals, nonstructurable materials. In addition to the compounds themselves, the Contractor must provide the Quality Control (QC) information (LCMS, H1 NMR) for all agents. This includes the HPLC purity trace, low-resolution mass spectral signature and proton NMR. Anticipated period of performance: Delivery within fifty (50) days after receipt of order (ARO). Other important considerations: In case domestic sources are available and capable of fulfilling the Government’s need, and a future solicitation is published, the Government will use evaluation preferences in accordance with FAR 25. Capability statement /information sought: Companies that believe they possess the capabilities to provide the required products or services should submit documentation of their ability to meet each of the project requirements to the Contracting Officer. The capability statement must specifically address each of the project requirements separately. Additionally, the capability statement should include 1) the total number of employees, 2) the professional qualifications of personnel as it relates to the requirements outlined, 3) any contractor GSA Schedule contracts and/or other government-wide acquisition contracts (GWACs) by which all of the requirements may be met, if applicable, and 4) any other information considered relevant to this program. Capability statements must also include the Company Name, Unique Entity ID from SAM.gov, Physical Address, and Point of Contact Information. The response must include the respondents’ technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. Interested companies are required to identify their type of business, applicable North American Industry Classification System (NAICS) Code, and size standards in accordance with the Small Business Administration. The government requests that no proprietary or confidential business data be submitted in a response to this notice. However, responses that indicate the information therein is proprietary will be properly safeguarded for Government use only. Capability statements must include the name and telephone number of a point of contact having authority and knowledge to discuss responses with Government representatives. Capability statements in response to this market survey that do not provide sufficient information for evaluation will be considered non-responsive. When submitting this information, please reference the solicitation notice number. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2” x 11” paper size, with 1” top, bottom, left and right margins, and with single or double spacing. The information submitted must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) page limit. The 10-page limit does not include the cover page, executive summary, or references, if requested. All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer. Facsimile responses are NOT accepted. The response must be submitted to Mark McNally, Contracting Officer, at mark.mcnally@nih.gov. The response must be received on or before 05:00 PM EDT, July 19, 2022. “Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in www.sam.gov. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).” 75N95022Q00405 Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse
7/12/22, 7:24 PM